Pepita Gimenez-Bonafe

Dr. Pepita Gimenez-Bonafe

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
PGPepita Gimenez-Bonafe
Pepita Gimenez-Bonafe
Avelina TortosaAvelina Tortosa
Avelina Tortosa
Ricardo Pérez-TomásRicardo Pérez-Tomás
Ricardo Pérez-Tomás
Drug resistance remains a major clinical challenge for cancer treatment. One mechanism by which tumor cells develop resistance to cytotoxic agents and radiation is related to resistance to apoptosis. Apoptosis is a well-organised process of cell death pre-programmed inside the cell. Apoptosis can be initiated either by activation of death receptors on the cell surface membranes (extrinsic pathway) or through a series of cellular events primarily processed at mitochondria (intrinsic pathway). Apoptosis has been shown to be important for tumorigenesis and cancer treatment. Defects in apoptosis can result in the expansion of a population of neoplastic cells. However, because the death of tumor cells induced by chemotherapy and radiotherapy is largely mediated by activation of apoptosis, inhibition of apoptosis will make tumor cells resistant to anti-tumor treatment. Herein, we will review the molecular changes that have the potential to cause apoptotic dysregulation, including activation of antiapoptotic factors (Bcl-2, BCLXL, Bfl1/A1 etc.), inactivation of pro-apoptotic effectors (p53, p53 pathway), and /or reinforcement of survival signals (Survivin, FLIP, NF-κB etc). Furthermore, we will discuss therapeutic intervention and/or strategies that can lower the threshold for apoptosis of tumor cells that could became useful approaches to treat cancer with special emphasis placed on the important priority to develop new cancer therapeutics toward tumor stem cells.

13 April 2007 in Neuropathology
Verified
Journal Article
Closed access
PDF file
JBJordi Bruna
Jordi Bruna
MBMarta Brell
Marta Brell
IFIsidre Ferrer
Isidre Ferrer
PGPepita Gimenez-Bonafe
Pepita Gimenez-Bonafe
Avelina TortosaAvelina Tortosa
Avelina Tortosa

5 January 2004 in The Prostate
Verified
Journal Article
Closed access
PDF file
PGPepita Gimenez-Bonafe
Pepita Gimenez-Bonafe
MFMatthew N. Fedoruk
Matthew N. Fedoruk
TWTanis G. Whitmore
Tanis G. Whitmore
MAMajid Akbari
Majid Akbari
JRJody L. Ralph
Jody L. Ralph
CNColleen C. Nelson
Colleen C. Nelson

5 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RVRuth Villalonga-Planells
Ruth Villalonga-Planells
LCLlorenç Coll-Mulet
Llorenç Coll-Mulet
FMFina Martínez-Soler
Fina Martínez-Soler
ECEsther Castaño
Esther Castaño
JAJuan-Jose Acebes
Juan-Jose Acebes
Avelina TortosaAvelina Tortosa
Avelina Tortosa
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Despite concerted efforts to improve current therapies and develop novel clinical approaches, patient survival remains poor. As such, increasing attention has focused on developing new therapeutic strategies that specifically target the apoptotic pathway in order to improve treatment responses. Recently, nutlins, small-molecule antagonists of MDM2, have been developed to inhibit p53-MDM2 interaction and activate p53 signaling in cancer cells. Glioma cell lines and primary cultured glioblastoma cells were treated with nutlin-3a. Nutlin-3a induced p53-dependent G1- and G2-M cell cycle arrest and apoptosis in glioma cell lines with normal TP53 status. In addition, nutlin-arrested glioma cells show morphological features of senescence and persistent induction of p21 protein. Furthermore, senescence induced by nutlin-3a might be depending on mTOR pathway activity. In wild-type TP53 primary cultured cells, exposure to nutlin-3a resulted in variable degrees of apoptosis as well as cellular features of senescence. Nutlin-3a-induced apoptosis and senescence were firmly dependent on the presence of functional p53, as revealed by the fact that glioblastoma cells with knockdown p53 with specific siRNA, or cells with mutated or functionally impaired p53 pathway, were completely insensitive to the drug. Finally, we also found that nutlin-3a increased response of glioma cells to radiation therapy. The results provide a basis for the rational use of MDM2 antagonists as a novel treatment option for glioblastoma patients.

1 October 2007 in European Journal of Pharmacology
Verified
Journal Article
Closed access
RFRoser Francisco
Roser Francisco
Ricardo Pérez-TomásRicardo Pérez-Tomás
Ricardo Pérez-Tomás
PGPepita Gimenez-Bonafe
Pepita Gimenez-Bonafe
VSVanessa Soto-Cerrato
Vanessa Soto-Cerrato
PGPol Giménez-Xavier
Pol Giménez-Xavier
SASantiago Ambrosio
Santiago Ambrosio

1 October 2011 in Radiotherapy and Oncology
Verified
Journal Article
Open access
MPMiguel A. Peña-Rico
Miguel A. Peña-Rico
MCMaría Nieves Calvo-Vidal
María Nieves Calvo-Vidal
RVRuth Villalonga-Planells
Ruth Villalonga-Planells
FMFina Martínez-Soler
Fina Martínez-Soler
PGPepita Gimenez-Bonafe
Pepita Gimenez-Bonafe
ACAnna Manzano Cuesta
Anna Manzano Cuesta
The TP53 induced glycolysis and apoptosis regulator (TIGAR) functions to lower fructose-2,6-bisphosphate (Fru-2,6-P(2)) levels in cells, consequently decreasing glycolysis and leading to the scavenging of reactive oxygen species (ROS), which correlate with a higher resistance to cell death. The decrease in intracellular ROS levels in response to TIGAR may also play a role in the ability of p53 to protect from the accumulation of genomic lesions. Given these good prospects of TIGAR for metabolic regulation and p53-response modulation, we analyzed the effects of TIGAR knockdown in U87MG and T98G glioblastoma-derived cell lines. After TIGAR-knockdown in glioblastoma cell lines, different metabolic parameters were assayed, showing an increase in Fru-2,6-P(2), lactate and ROS levels, with a concomitant decrease in reduced glutathione (GSH) levels. In addition, cell growth was inhibited without evidence of apoptotic or autophagic cell death. In contrast, a clear senescent phenotype was observed. We also found that TIGAR protein levels were increased shortly after irradiation. In addition, avoiding radiotherapy-triggered TIGAR induction by gene silencing resulted in the loss of capacity of glioblastoma cells to form colonies in culture and the delay of DNA repair mechanisms, based in γ-H2AX foci, leading cells to undergo morphological changes compatible with a senescent phenotype. Thus, the results obtained raised the possibility to consider TIGAR as a therapeutic target to increase radiotherapy effects. TIGAR abrogation provides a novel adjunctive therapeutic strategy against glial tumors by increasing radiation-induced cell impairment, thus allowing the use of lower radiotherapeutic doses.